

1 ***Toxoplasma gondii* infection and insomnia: a case control**  
2 **seroprevalence study**

3

4 Short title: *Toxoplasma* and insomnia.

5

6 Cosme Alvarado-Esquivel<sup>1</sup>, Sergio Estrada-Martínez<sup>2</sup>, Alma Rosa Pérez-Álamos,<sup>2</sup> Agar  
7 Ramos-Nevarez,<sup>3</sup> Karina Botello-Calderon,<sup>1</sup> Ángel Osvaldo Alvarado-Félix,<sup>1</sup> Raquel  
8 Vaquera-Enríquez,<sup>4</sup> Gustavo Alexis Alvarado-Félix,<sup>1</sup> Antonio Sifuentes-Alvarez<sup>1</sup>, Carlos  
9 Alberto Guido-Arreola,<sup>3</sup> Elizabeth Rábago-Sánchez<sup>1</sup>, Leandro Saenz-Soto.<sup>3</sup>

10

11 <sup>1</sup>Biomedical Research Laboratory. Faculty of Medicine and Nutrition, Juárez University of  
12 Durango State. Avenida Universidad S/N. 34000 Durango, Mexico.

13 <sup>2</sup>Institute for Scientific Research “Dr. Roberto Rivera-Damm”, Juárez University of Durango  
14 State. Avenida Universidad S/N. 34000 Durango, Mexico.

15 <sup>3</sup>Clínica de Medicina Familiar. Instituto de Seguridad y Servicios Sociales de los  
16 Trabajadores del Estado. Predio Canoas S/N. 34079 Durango, Mexico.

17 <sup>4</sup>Health Center No. 2 “Dr. Carlos Santamaría”. Servicios de Salud de Durango. Durango,  
18 Mexico. Talpa S/N. 34170 Durango, Mexico.

19

20

21 Corresponding author:

22 Dr. Cosme Alvarado-Esquivel. Laboratorio de Investigación Biomédica. Facultad de  
23 Medicina y Nutrición. Avenida Universidad S/N. 34000 Durango, Dgo, México. Tel/Fax:  
24 0052-618-8271380. Email: cosmealvarado@ujed.mx

25

26

27 **E-mail addresses:**

28 CAE: alvaradocosme@yahoo.com

29 SEM: semdurango@hotmail.com

30 ARPA: almaross1@yahoo.es

31 ARN: agar\_ramos@hotmail.com

32 KBC: kary09botellocalderon@gmail.com

33 AOAF: aoafangel@hotmail.com

34 RVE: raqueenriquez@hotmail.com

35 GAAF: gaafalexis15@gmail.com

36 ASA: sifual55@hotmail.com

37 CAGA: drguido1@hotmail.com

38 ERS: rabagopediatria@hotmail.com

39 LSS: quim\_saenz@hotmail.com

40

41

42

43

44

46 **ABSTRACT**

47 **Aim:** To determine the association between *Toxoplasma gondii* (*T. gondii*) infection and  
48 insomnia.

49 **Materials and methods:** Through an age-and gender-matched case-control study, 577  
50 people with insomnia (cases) and 577 people without insomnia (controls) were tested for  
51 anti-*T. gondii* IgG and IgM antibodies using commercially available enzyme-immunoassays.

52 **Results:** Anti-*T. gondii* IgG antibodies were found in 71 (12.3%) of 577 individuals with  
53 insomnia and in 46 (8.0%) of 577 controls (OR=1.62; 95% CI: 1.09-2.39; *P*=0.01). Men with  
54 insomnia had a higher (16/73: 21.9%) seroprevalence of *T. gondii* infection than men without  
55 insomnia (5/73: 6.8%) (OR: 3.81; 95% CI: 1.31-11.06; *P*=0.009). The rate of high (>150  
56 IU/ml) anti-*T. gondii* IgG antibody levels in cases was higher than the one in controls  
57 (OR=2.21; 95% CI: 1.13-4.31; *P*=0.01). Men with insomnia had a higher (8/73: 11.0%) rate  
58 of high anti-*T. gondii* IgG antibody levels than men without insomnia (0/73: 0.0%)  
59 (*P*=0.006). The rate of high anti-*T. gondii* IgG antibody levels in cases >50 years old (11/180:  
60 6.1%) was higher than that (3/180: 1.7%) in controls of the same age group (OR: 3.84; 95%  
61 CI: 1.05-14.00; *P*=0.05). No difference in the rate of IgM seropositivity between cases and  
62 controls was found (OR=1.33; 95% CI: 0.57-3.11; *P*=0.50).

63 **Conclusions:** Results of this seroepidemiology study suggest that infection with *T. gondii* is  
64 associated with insomnia. Men older than 50 years with *T. gondii* exposure might be prone  
65 to insomnia. Further research to confirm the association between seropositivity and  
66 serointensity to *T. gondii* and insomnia are needed.

67

68

69

70 **Keywords:**

71 *Toxoplasma gondii*; insomnia; case-control study; seroprevalence; epidemiology.

72

73

## 75 **Introduction**

76 *Toxoplasma gondii* (*T. gondii*) is an obligate intracellular parasite [1]. Toxoplasmosis,  
77 the disease caused by *T. gondii*, is a zoonosis with medical and veterinary importance  
78 worldwide [2]. *T. gondii* infects one third of the global human population [3]. Foodborne  
79 transmission of *T. gondii* in humans occurs mainly by eating undercooked meat, especially  
80 pork, lamb, and wild game meat from *T. gondii*-infected animals, and ingestion of raw fruits  
81 and vegetables contaminated with soil containing cat feces [4]. Transmission of *T. gondii*  
82 may also occur by blood transfusion, tissue transplants, or ingestion of unpasteurized milk  
83 [5]. In addition, *T. gondii* can be transmitted vertically during pregnancy [6]. Infections with  
84 *T. gondii* may result in a clinical spectrum ranging from a completely asymptomatic infection  
85 to multi-organ involvement [7]. Some patients with toxoplasmosis present cervical  
86 lymphadenopathy or ocular disease, whereas a reactivation of latent disease in  
87 immunocompromised patients can cause life-threatening encephalitis [8]. Chronic  
88 toxoplasmosis might be responsible for a vast array of neuropsychiatric symptoms [9].  
89 Seroprevalence of *T. gondii* infection has been linked to mixed anxiety and depressive  
90 disorder [10], schizophrenia [11, 12], depression [13, 14], and suicide behavior [14-15]. Few  
91 studies have shown a link between *T. gondii* infection and insomnia. However, results of  
92 such studies are controversial. In a study of students, a positive association between  
93 seropositivity to *T. gondii* and insomnia was found in women but not in men [16]. In two  
94 further studies, researchers found that *T. gondii* IgG seropositivity and serointensity were not  
95 associated with insomnia [17, 18]. *T. gondii* can disseminate to brain in infected hosts [19],  
96 and we hypothesize that *T. gondii* can involve brain structures related with sleep leading to  
97 sleep problems as insomnia. Several neurotransmitters are involved in sleep including for

98 instance, dopamine and gamma-aminobutyric acid (GABA) [20], and *T. gondii* infections  
99 impact on these two neurotransmitters. *T. gondii* infections alter the dopamine metabolism  
100 [21], and GABAergic synapses and signaling in the central nervous system [22]. Therefore,  
101 this study was aimed to determine the association between *T. gondii* exposure and insomnia  
102 in a sample of people in Durango, Mexico.

## 104 **Methods**

### 105 **Study design and study population**

106 Through a cross-sectional, age- and gender-matched case-control study, 577 people  
107 with insomnia (cases) and 577 people without insomnia (controls) were examined for the  
108 presence of *T. gondii* exposure. This study was performed in the northern Mexican state of  
109 Durango from 2014 to 2019. Cases and controls were individuals attending public health care  
110 institutions for medical consultations or laboratory tests. Inclusion criteria for cases were  
111 people with insomnia, aged  $\geq 18$  years, with informed consent. Gender, occupation, and  
112 socioeconomic status were not restrictive criteria for enrollment of cases or controls. The  
113 Diagnostic and Statistical Manual of Mental Disorders, Fifth edition (DSM-5) defines  
114 insomnia as a predominant complain of dissatisfaction with sleep quantity or quality,  
115 associated with one (or more) of the following symptoms: difficulty initiating sleep,  
116 difficulty maintaining sleep, and early-morning awakening with inability to return to sleep  
117 [23]. Inclusion criteria for enrollment of controls were people without insomnia, aged  $\geq 18$   
118 years, with informed consent. Of the 577 cases, 505 (87.5%) were women and 72 (12.5%)  
119 were men. They were 18-80 years old (mean:  $43.63 \pm 12.55$ ). Whereas of the 577 controls,  
120 503 (87.2%) were women and 74 (12.8%) were men. They were 18-81 years old (mean:  
121  $43.63 \pm 12.56$ ). There were no differences in age ( $P=0.99$ ) or gender ( $P=0.93$ ) among cases  
122 and controls.

123

### 124 **Laboratory tests**

125 Five ml of venous blood was drawn from each participant. After blood clotting, blood  
126 samples were centrifuged. Serum was transferred into microtubes and kept at  $-20^{\circ}$  C until

127 assayed. All samples were analyzed for anti-*T. gondii* IgG antibodies using the commercially  
128 available enzyme-linked immunoassay “*Toxoplasma gondii* IgG” kit (Diagnostic  
129 Automation/Cortez Diagnostics, Inc., Woodland Hills, California. USA). This test allows  
130 detection and quantification of anti-*T. gondii* IgG antibodies. A cut-off of 8 IU/ml was used  
131 to determine seropositivity. Serum samples with anti-*T. gondii* IgG antibodies were further  
132 analyzed for detection of anti-*T. gondii* IgM antibodies by the commercially available  
133 enzyme-linked immunoassay “*Toxoplasma gondii* IgM” kit (Diagnostic Automation/Cortez  
134 Diagnostics, Inc.). Positive and negative controls were included in each run. All  
135 immunoassays were carried out as described in the manufacturer’s instructions.

136

### 137 **Statistical analysis**

138 Data analysis was performed using the software SPSS Statistics version 15. A sample  
139 size of 577 cases and 577 controls was calculated using the following parameters: a reference  
140 seroprevalence of 6.1% [24] as the expected frequency of exposure in controls, a two-sided  
141 confidence level of 95%, a power of 90%, a 1:1 proportion of cases and controls, and an odds  
142 ratio of 2.0. The student’s t-test was used to assess age matching. To compare the frequencies  
143 among the groups the Pearson’s chi-square test or the Fisher’s exact test (when a value was  
144 below 5) were used. Odd ratios (OR) and corresponding 95% confidence intervals (CI) were  
145 calculated. A statistical *P* value of  $\leq 0.05$  was considered significant for all comparisons.

146

### 147 **Ethical aspects**

148 The Ethical Committees of the Institute of Security and Social Services for the State  
149 Workers and the General Hospital of the Secretary of Health in Durango City, Mexico  
150 approved this project. A written informed consent from each participant was obtained.





## 153 **Results**

154           Anti-*T. gondii* IgG antibodies were found in 71 (12.3%) of 577 individuals with  
155 insomnia and in 46 (8.0%) of 577 controls. A statistically significant difference (OR=1.62;  
156 95% CI: 1.09-2.39;  $P=0.01$ ) in anti-*T. gondii* IgG seroprevalence between cases and controls  
157 was found. A stratification by age and sex and seroprevalence of *T. gondii* infection in  
158 individuals with and without insomnia is shown in Table 1. Stratification by sex showed that  
159 men with insomnia had a significantly higher (16/73: 21.9%) seroprevalence of *T. gondii*  
160 infection than men without insomnia (5/73: 6.8%) (OR: 3.81; 95% CI: 1.31-11.06;  $P=0.009$ ).  
161 Whereas stratification by age groups showed that seroprevalence of *T. gondii* infection in  
162 cases was similar to controls regardless their age groups. Of the 71 anti-*T. gondii* IgG positive  
163 cases, 28 (39.4%) had anti-*T. gondii* IgG antibody levels higher than 150 IU/ml, 6 (8.5%)  
164 between 100 IU/ml and 150 IU/ml, and 37 (52.1%) between 8 to 99 IU/ml. On the other  
165 hand, of the 46 anti-*T. gondii* IgG positive controls, 13 (28.2%) had anti-*T. gondii* IgG  
166 antibody levels higher than 150 IU/ml, 5 (10.9%) between 100 IU/ml and 150 IU/ml, and 28  
167 (60.9%) between 8 to 99 IU/ml. A statistically significant difference (OR=2.21; 95% CI:  
168 1.13-4.31;  $P=0.01$ ) in the frequency of individuals with high (>150 IU/ml) anti-*T. gondii* IgG  
169 antibody levels between cases and controls was found. A stratification by sex and age groups  
170 and the rates of high (>150 IU/ml) anti-*T. gondii* IgG antibody levels in cases and controls is  
171 shown in Table 2. Stratification by sex showed that men with insomnia had a significantly  
172 higher (8/73: 11.0%) rate of high anti-*T. gondii* IgG antibody levels than men without  
173 insomnia (0/73: 0.0%) ( $P=0.006$ ). Whereas stratification by age groups showed that the rate  
174 of high anti-*T. gondii* IgG antibody levels in cases >50 years old (11/180: 6.1%) was higher  
175 than that (3/180: 1.7%) in controls of the same age group (OR: 3.84; 95% CI: 1.05-14.00;

176  $P=0.05$ ). Of the 71 anti-*T. gondii* IgG antibody seropositive cases, 21 (29.6%) were also  
177 positive for anti-*T. gondii* IgM antibodies. Whereas, of the 46 anti-*T. gondii* IgG antibody  
178 seropositive controls, 11 (23.9%) were also positive for anti-*T. gondii* IgM antibodies. No  
179 difference in the rate of IgM seropositivity between cases and controls was found (OR=1.33;  
180 95% CI: 0.57-3.11;  $P=0.50$ ).

181

182

183

184

185

186

187

188

189

190

## 192 **Discussion**

193           There are only few studies that have assessed the epidemiological link between *T.*  
194 *gondii* infection and insomnia. Results of such studies are controversial and there is currently  
195 scanty information as to state whether *T. gondii* exposure leads to insomnia. Therefore, in  
196 this age- and gender-matched case-control study we attempted to determine the association  
197 between *T. gondii* exposure and insomnia in a sample of people in the northern Mexican state  
198 of Durango. We observed a significantly higher seroprevalence of *T. gondii* infection in  
199 individuals with insomnia than in individuals without insomnia. In addition, we found a  
200 significantly higher rate of high anti-*T. gondii* IgG antibody levels in cases than in controls.  
201 Therefore, our results suggest that *T. gondii* seropositivity and serointensity are positively  
202 associated with insomnia. However, the association of *T. gondii* seropositivity and insomnia  
203 was observed in men but not in women, and the association between *T. gondii* serointensity  
204 and insomnia was found only in men and in individuals aged >50 years. The positive  
205 association between *T. gondii* seropositivity and insomnia found in our study contrast with  
206 that found in a previous study of 200 students in Iran, where investigators observed a positive  
207 association between *T. gondii* seroprevalence and insomnia in women but not in men [16]. It  
208 is not clear why the association between seropositivity and insomnia was found only in men  
209 in our study. It is unknown whether men are more vulnerable than women to the clinical  
210 effects of *T. gondii*. It is possible that factors associated with *T. gondii* exposure in men were  
211 different from those in women in our study. Further research to determine the association  
212 between sociodemographic, clinical, and behavioral factors and *T. gondii* exposure in men  
213 with insomnia is needed. On the other hand, results of our study also contrast with the  
214 findings of two more studies. In a study of 311 older adults recruited in a psychiatric institute

215 and clinic in Pittsburg, USA, researchers found no association between insomnia and *T.*  
216 *gondii* seroprevalence and serointensity [17]. In a study of 2031 Old Order Amish individuals  
217 recruited in Lancaster County, USA, researchers found no association between *T. gondii*  
218 seropositivity and serointensity and insomnia [18]. Difference in the association between *T.*  
219 *gondii* exposure and insomnia among the studies might be due to differences in the  
220 characteristics of the study populations. We studied people enrolled at several health care  
221 institutions whereas researchers of other studies enrolled students [16], older adults [17], and  
222 Old Order Amish individuals [18]. In addition, there are differences in the sample size and  
223 study design among the studies. We used an age- and gender-matched case-control study  
224 design and studied 577 cases and 577 controls whereas in another study 180 people suffering  
225 from insomnia and 131 normal sleeping participants with no differences in age, gender and  
226 race were studied [17]. The study of students was cross-sectional and had 200 participants  
227 [16]; and the study of Old Order Amish was cross-sectional and included 2031 participants  
228 [18]. Risk factors for *T. gondii* exposure and host factors might be different among the study  
229 populations. In addition, differences in the virulence of *T. gondii* strains among infected hosts  
230 might exist. Further research to determine the association between insomnia and *T. gondii*  
231 seropositivity and serointensity are needed.

232

### 233 **Conclusions:**

234 Results of this age- and gender-matched case-control study suggest that infection with  
235 *T. gondii* is associated with insomnia. Men older than 50 years with *T. gondii* exposure might  
236 be prone to insomnia. Further research to confirm the association between seropositivity and  
237 serointensity to *T. gondii* and insomnia are needed.

238

239 **Conflict of interest:**

240           The authors declare that no conflict of interest exists.

241

242 **Funding:**

243           This study was financially supported by Secretary of Public Education, Mexico

244 (Grant No. DSA/103.5/14/11311).

245

246

247

249 **References**

- 250 1. Robert-Gangneux F, Dardé ML. Epidemiology of and diagnostic strategies for  
251 toxoplasmosis. Clin Microbiol Rev. 2012 Apr;25(2):264-96. doi: 10.1128/CMR.05013-11.  
252
- 253 2. Liu Q, Wang ZD, Huang SY, Zhu XQ. Diagnosis of toxoplasmosis and typing of  
254 *Toxoplasma gondii*. Parasit Vectors. 2015 May 28;8:292. doi: 10.1186/s13071-015-0902-6.  
255
- 256 3. Schlüter D, Barragan A. Advances and Challenges in Understanding Cerebral  
257 Toxoplasmosis. Front Immunol. 2019 Feb 14;10:242. doi: 10.3389/fimmu.2019.00242.  
258
- 259 4. Jones JL, Dubey JP. Foodborne toxoplasmosis. Clin Infect Dis. 2012 Sep;55(6):845-51.  
260 doi: 10.1093/cid/cis508.  
261
- 262 5. Tenter AM, Heckeroth AR, Weiss LM. *Toxoplasma gondii*: from animals to humans. Int  
263 J Parasitol. 2000 Nov;30(12-13):1217-58. doi: 10.1016/s0020-7519(00)00124-7.  
264
- 265 6. Rajapakse S, Weeratunga P, Rodrigo C, de Silva NL, Fernando SD. Prophylaxis of human  
266 toxoplasmosis: a systematic review. Pathog Glob Health. 2017 Oct;111(7):333-342. doi:  
267 10.1080/20477724.2017.1370528.  
268
- 269 7. Fabiani S, Pinto B, Bruschi F. Toxoplasmosis and neuropsychiatric diseases: can  
270 serological studies establish a clear relationship? Neurol Sci. 2013 Apr;34(4):417-25. doi:  
271 10.1007/s10072-012-1197-4.

272

273 8. Montoya JG, Liesenfeld O. Toxoplasmosis. *Lancet*. 2004 Jun 12;363(9425):1965-76. doi:  
274 10.1016/S0140-6736(04)16412-X.

275

276 9. Fuglewicz AJ, Piotrowski P, Stodolak A. Relationship between toxoplasmosis and  
277 schizophrenia: A review. *Adv Clin Exp Med*. 2017 Sep;26(6):1031-1036. doi:  
278 10.17219/acem/61435.

279

280 10. Alvarado-Esquivel C, Sanchez-Anguiano LF, Hernandez-Tinoco J, Berumen-Segovia  
281 LO, Torres-Prieto YE, Estrada-Martinez S, Perez-Alamos AR, Ortiz-Jurado MN, Molotla-  
282 de-Leon G, Beristain Garcia I, Rabago-Sanchez E, Liesenfeld O. *Toxoplasma gondii*  
283 infection and mixed anxiety and depressive disorder: a case-control seroprevalence study in  
284 Durango, Mexico. *J Clin Med Res*. 2016 Jul;8(7):519-23. doi: 10.14740/jocmr2576w.

285

286 11. Stepanova EV, Kondrashin AV, Sergiev VP, Morozova LF, Turbabina NA, Maksimova  
287 MS, Romanov DV, Kinkulkina MA, Lazareva AV, Morozov EN. Toxoplasmosis and mental  
288 disorders in the Russian Federation (with special reference to schizophrenia). *PLoS One*.  
289 2019 Jul 10;14(7):e0219454. doi: 10.1371/journal.pone.0219454.

290

291 12. Alvarado-Esquivel C, Urbina-Álvarez JD, Estrada-Martínez S, Torres-Castorena A,  
292 Molotla-de-León G, Liesenfeld O, Dubey JP. *Toxoplasma gondii* infection and  
293 schizophrenia: a case control study in a low *Toxoplasma* seroprevalence Mexican population.  
294 *Parasitol Int*. 2011 Jun;60(2):151-5. doi: 10.1016/j.parint.2010.12.003.

295



- 296 13. Alvarado-Esquivel C, Sánchez-Anguiano LF, Hernández-Tinoco J, Berumen-Segovia  
297 LO, Torres-Prieto YE, Estrada-Martínez S, Pérez-Álamos AR, Ortiz-Jurado MN, Molotla-  
298 de-León G, Beristain-García I, Rábago-Sánchez E, Liesenfeld O. *Toxoplasma gondii*  
299 infection and depression: a case-control seroprevalence study. *Eur J Microbiol Immunol*  
300 (Bp). 2016 Apr 25;6(2):85-9. doi: 10.1556/1886.2016.00010.
- 301
- 302 14. Kamal AM, Kamal AM, Abd El-Fatah AS, Rizk MM, Hassan EE. Latent toxoplasmosis  
303 is associated with depression and suicidal behavior. *Arch Suicide Res.* 2020 Nov 9:1-12. doi:  
304 10.1080/13811118.2020.1838368.
- 305
- 306 15. Alvarado-Esquivel C, Estrada-Martínez S, Ramos-Nevárez A, Pérez-Álamos AR,  
307 Beristain-García I, Alvarado-Félix AO, Cerrillo-Soto SM, Sifuentes-Álvarez A, Alvarado-  
308 Félix GA, Guido-Arreola CA, Saenz-Soto L. Association between *Toxoplasma gondii*  
309 exposure and suicidal behavior in patients attending primary health care clinics. *Pathogens.*  
310 2021 May 30;10(6):677. doi: 10.3390/pathogens10060677.
- 311
- 312 16. Khademvatan S, Izadi-Mazidi M, Saki J, Khajeddin N. Mental health and latent  
313 toxoplasmosis: comparison of individuals with and without anti-*Toxoplasma* antibodies.  
314 *World Health Popul.* 2016;17(1):39-46. doi: 10.12927/whp.2016.24938.
- 315
- 316 17. Meshreky KM, Wood J, Chowdari KV, Hall MH, Wilckens KA, Yolken R, Buysse DJ,  
317 Nimgaonkar VL. Infection with Herpes Simplex virus type 1 (HSV-1) and sleep: The dog  
318 that did not bark. *Psychiatry Res.* 2019 Oct;280:112502. doi:  
319 10.1016/j.psychres.2019.112502.

320

321 18. Ahmad Z, Moustafa YW, Stiller JW, Pavlovich MA, Raheja UK, Gragnoli C, Snitker S,  
322 Nazem S, Dagdag A, Fang B, Fuchs D, Lowry CA, Postolache TT. Sleep onset insomnia,  
323 daytime sleepiness and sleep duration in relationship to *Toxoplasma gondii* IgG  
324 seropositivity and serointensity. *Pteridines*. 2017;28(3-4):195-204. doi: 10.1515/pterid-  
325 2017-0010.

326

327 19. Schlüter D, Barragan A. Advances and Challenges in Understanding Cerebral  
328 Toxoplasmosis. *Front Immunol*. 2019 Feb 14;10:242. doi: 10.3389/fimmu.2019.00242.

329

330 20. Murillo-Rodriguez E, Arias-Carrion O, Zavala-Garcia A, Sarro-Ramirez A, Huitron-  
331 Resendiz S, Arankowsky-Sandoval G. Basic sleep mechanisms: an integrative review. *Cent*  
332 *Nerv Syst Agents Med Chem*. 2012 Mar;12(1):38-54. doi: 10.2174/187152412800229107.

333

334 21. Parlog A, Schlüter D, Dunay IR. *Toxoplasma gondii*-induced neuronal alterations.  
335 *Parasite Immunol*. 2015 Mar;37(3):159-70. doi: 10.1111/pim.12157.

336

337 22. Brooks JM, Carrillo GL, Su J, Lindsay DS, Fox MA, Blader IJ. *Toxoplasma gondii*  
338 infections alter GABAergic synapses and signaling in the central nervous system. *mBio*.  
339 2015 Oct 27;6(6):e01428-15. doi: 10.1128/mBio.01428-15.

340

341 23. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental*  
342 *Disorders*. 5th ed. Arlington: American Psychiatric Publishing; 2013.

343

344 24. Alvarado-Esquivel C, Estrada-Martínez S, Pizarro-Villalobos H, Arce-Quiñones M,  
345 Liesenfeld O, Dubey JP. Seroepidemiology of *Toxoplasma gondii* infection in general  
346 population in a northern Mexican city. *J Parasitol.* 2011 Feb;97(1):40-3. doi: 10.1645/GE-  
347 2612.1.

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

**Table 1. Stratification by sex and age in cases and controls and seropositivity rates to *T. gondii*.**

Characteristics	Cases			Controls			Odds ratio	95% confidence interval	<i>P</i> value
	No. tested	Seropositivity to <i>T. gondii</i>		No. tested	Seropositivity to <i>T. gondii</i>				
		No.	%		No.	%			
<b>Sex</b>									
Male	73	16	21.9	73	5	6.8	3.81	1.31 - 11.06	0.009
Female	504	55	10.9	504	41	8.1	1.38	0.90 - 2.11	0.13
<b>Age (years)</b>									
≤30	99	9	9.1	99	5	5.1	1.80	0.60 - 5.82	0.26
31-50	298	37	12.4	298	27	9.1	1.42	0.84 - 2.40	0.18
>50	180	25	13.9	180	14	7.8	1.91	0.96 - 3.81	0.06
<b>All</b>	<b>577</b>	<b>71</b>	<b>12.3</b>	<b>577</b>	<b>46</b>	<b>8.0</b>	<b>1.62</b>	<b>1.09 - 2.39</b>	<b>0.01</b>

363

364

365

366

367

**Table 2. Stratification by sex and age in cases and controls and rates of high ( $\geq 150$  IU/ml) anti-*T. gondii* IgG antibody levels.**

Characteristics	Cases			Controls			Odds ratio	confidence interval	P value
	No. tested	$\geq 150$ IU/ml anti- <i>T. gondii</i> IgG levels		No. tested	$\geq 150$ IU/ml anti- <i>T. gondii</i> IgG levels				
		No.	%		No.	%			
<b>Sex</b>									
Male	73	8	11.0	73	0	0.0	--	---	0.006
Female	504	20	4.0	504	13	2.6	1.56	0.76-3.17	0.21
<b>Age (years)</b>									
$\leq 30$	99	4	4.0	99	1	1.0	4.12	0.45-37.60	0.36
31-50	298	13	4.4	298	9	3.0	1.46	0.61-3.48	0.38
$> 50$	180	11	6.1	180	3	1.7	3.84	1.05-14.00	0.05
<b>All</b>	<b>577</b>	<b>28</b>	<b>4.9</b>	<b>577</b>	<b>13</b>	<b>2.3</b>	<b>2.21</b>	<b>1.13-4.31</b>	<b>0.01</b>

368

369

370

371

372